[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"London North West Healthcare NHS Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":198},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,67,94,116,154,175],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100615903","3d-contrast-enhanced-microvascular-ultrasound-of-carotid-atherosclerosis-for-the-detection-of-carotid-plaque-neo-revascularisation-100615903",false,"NCT07298655","3D Contrast Enhanced Microvascular Ultrasound of Carotid Atherosclerosis for the Detection of Carotid Plaque Neo-Revascularisation.","Carotid Neo3D","Inclusion Criteria:\n\n1. Age\\>18 years old.\n2. Previously consent for participation in the SECURE trial and have undergone carotid CEUS.\n3. Found to have at least one carotid plaque present on carotid CEUS.\n4. Able to give informed consent to participate in the study and its procedures.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years old.\n2. Unable to provide informed consent to participate in the study and its procedures.\n3. Allergy to microbubble contrast agents.\n4. Known pregnancy.","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","Atherosclerotic plaques, the build-up of fatty materials within our arteries, can develop over a long period of time without causing any symptoms.\n\nThese plaques may continue to grow and rupture causing narrowing and blockages of the blood vessels. This can lead to serious cardiovascular disease such as a heart attack or stroke causing over 160,000 deaths each year.\n\nLots of research has been done on why particular groups of people may develop atherosclerosis and controlling risk factors such as diabetes and high blood pressure go a long way to reduce people's risks. However, despite the treatments we have available and controlling these risk factors, some people unfortunately still go on to develop a potentially serious disease.\n\nFurther research has shown us that certain plaques in the blood vessels may be more vulnerable to rupturing compared to others. So far we know that plaques with thin caps, soft centres or those that are able to grow their own tiny blood vessels are more likely to rupture. We have now started to develop new imaging methods to try and help us detect these vulnerabilities. The hope is by being able to detect more vulnerable plaques we may be able to treat these earlier and therefore more effectively.\n\nThere are different scans available to try and visualise the tiny vessels within these plaques in the neck arteries. These include, MRI (a Magnetic Resonance Imaging scan, taking pictures using a small tunnel), CT (Computed Tomography, uses a ring-shaped machine to take pictures), and ultrasound. Ultrasound has the benefit of being free of ionising radiation and iodinated contrast, therefore posing less risk to patients. However, current ultrasound uses 2D ultrasound. Although this has shown promising results, our blood vessels and any plaques are 3D structures so we don't get to see the whole plaque using 2D imaging and therefore may miss important information. The available 3D probes in use at the moment are not able to visualise the tiny vessels accurately enough.\n\nThis study uses a different 3D ultrasound probe and ultrasound machine that is able to produce many more images than our usual probes. By taking images with this probe and using offline computer programmes to track the contrast through structures we hope that this system will be able to give us a visualisation of the whole plaque enabling us to detect any new blood vessels more accurately.",[26,27,28],"Carotid Atherosclerosis","Ultrasound","Plaque Neovascularization",[30,31,32],"Carotid atherosclerosis","Carotid Ultrasound","Plaque Neovascularisation","RECRUITING","2026-04-09",{"date":36,"type":37},"2026-04-13","ACTUAL",{"date":39,"type":37},"2025-10-16",{"date":41,"type":20},"2026-09-30",{"name":43,"class":44},"London North West Healthcare NHS Trust","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":45},"100613797","a-randomised-paired-design-study-of-texture-and-colour-enhancement-imaging-txi-versus-high-definition-white-light-endoscopy-100613797","NCT07271264","A Randomised Paired Design Study of Texture and Colour Enhancement Imaging (TXI) Versus High-definition White Light Endoscopy","A Randomised Paired Design Study of Texture and Colour Enhancement Imaging (TXI) Versus High-definition White Light Endoscopy for Dysplasia Detection in IBD Surveillance.","Inclusion Criteria:\n\n* Patients \\>16 with inflammatory bowel disease undergoing surveillance colonoscopy.\n* Patients with Crohn's (L2\u002FL3 Montreal classification) with \\>50% colonic involvement OR\n* Patients with ulcerative colitis with Extensive or left sided disease (E3 or E2 Montreal classification) for at least 8 years or a diagnosis of Primary sclerosing cholangitis concomitant with IBD.\n\nExclusion Criteria:\n\n* Disease duration \\\u003C8 years unless a diagnosis of PSC\n* Incomplete colonoscopy\n* BBPS \\\u003C6 or \\\u003C2 in any segment\n* MES ≥2 or any variable of the SES-CD is ≥2 or any stenosis for \\>10cm segment (above the rectum)\n* Previous colorectal resection\n* Thrombocytopaenia (platelet count \\\u003C50) or Coagulopathy precluding biopsy\n* Anticoagulation that has not been held appropriately prior to the procedure (must be held at least the morning of the procedure).\n* Pregnancy\n* Unable or unwilling to consent to study participation","16 Years",{"count":55,"type":20},219,[23],"Texture and Colour Enhancement Imaging (TXI) improves texture, brightness, and colour in white-light endoscopy to highlight subtle tissue differences. Now available through the EVIS X1 system, early evidence suggests potential value in IBD. Studies show that TXI may help predict ulcerative colitis relapse and performs comparably to dye chromoendoscopy in detecting lesions, though no randomised data exist for dysplasia detection in IBD surveillance. We therefore propose a randomised paired study comparing TXI with high-definition white-light endoscopy for dysplasia detection in IBD surveillance.",[59],"IBD","2026-04-07",{"date":36,"type":37},{"date":63,"type":37},"2025-12-08",{"date":65,"type":20},"2029-03-30",{"name":43,"class":44},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":45},"100530342","secure-trial-stress-echocardiography-with-carotid-ultrasound-vs-routine-ct-coronary-angiography-in-chronic-coronary-syndrome-for-endpoints-100530342","NCT06185530","SECURE Trial: Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Chronic Coronary Syndrome for Endpoints","Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Suspected Chronic Coronary Syndrome for the Detection of Obstructive Coronary Disease and Prevention of Adverse Outcomes.","SECURE","Inclusion Criteria:\n\n1. Age \\> 18 years old\n2. Patients referred to RACPC and judged by the reviewer to require a further imaging investigation, either SE or CTCA, to evaluate a suspected diagnosis of CAD\n3. AND\n\n   1. Have a PTP score ≥ 5%, as calculated using ESC guidelines OR\n   2. Have clinical history in keeping with 'typical' angina symptoms, as judged by the investigator, in patients with a PTP score \\\u003C5% - With 'typical' symptoms, as per ESC guidelines, being all three of the following\n\n   i) Constricting symptoms in the front of the chest or in the neck, jaw, shoulder or arm ii) Precipitated by physical exertion iii) Relieved by rest or nitrates within 5 minutes\n4. Able to give informed consent to participate in the study and its follow up\n\nExclusion Criteria:\n\n1. Patients with diagnosed ACS that require urgent or emergency treatment or hospitalisation for inpatient investigations.\n2. Known history of obstructive CAD (Previous MI, PCI or CABG) or previous invasive angiography with evidence of ≥ 50% stenosis in any epicardial vessel.\n3. Patients who have undergone invasive or non-invasive, functional or anatomical (Including CAC score) testing for detection of CAD within the previous 1 year of clinical assessment.\n4. Documented allergy to iodinated contrast or documented allergy to both ultrasound contrasts used at LNWH Trust; Luminity® (Perflutren) and SonoVue® (Sulphur Hexafluoride) or the constitutes\n5. Contraindications to undergoing CTCA, including but not limited to;\n\n   * eGFR \\\u003C 40 ml\u002Fmin\n   * Contraindications to beta-blockers including but not limited to, documented allergy or significant airways disease in the judgement of the investigator.\n   * Exceeding CT scanner weight tolerance\n6. Contraindications to undergoing SE, including but not limited to;\n\n   * Known cardiomyopathic process (Hypertrophic cardiomyopathy (HCM)) with resting gradient \\> 50mmHg or severe valvular lesion\n   * Severe uncontrolled hypertension (≥180\u002F100mmHg)\n7. Known pregnancy\n8. Unable to provide informed consent",{"count":76,"type":20},2000,[23],"Diseases of the heart and circulation are known as cardiovascular diseases, and they cause over 160,000 deaths each year.\n\nCoronary heart disease (CHD) is the most common cardiovascular disease. This is due to a build-up of fatty material, known as atherosclerosis, in the blood vessels supplying blood to the heart muscle. This can cause chest pain or if blocked, can cause a heart attack.\n\nTwo of the main non-invasive tests to look for coronary heart disease are Computed Tomography Coronary Angiography (CTCA) and Stress Echocardiography (Ultrasound scan).\n\nCTCA shows the arteries and allows small amounts of disease to be seen that may not yet be causing any symptoms. However, if there's lots of disease and calcification, it becomes difficult to tell how severe it is, which means several tests may be needed. Stress Echocardiography shows if enough blood is reaching the heart muscle, so can show if there is severe disease that needs treatment. However, it can't see the arteries so doesn't showt small disease that may benefit from tablet treatment. There is not yet an effective non-invasive combined test that can give all this information in one go.\n\nStudies have shown that if there's atherosclerosis in another artery, a person is very likely to have coronary atherosclerosis as well. Carotid atherosclerosis, in the neck arteries, can be seen with ultrasound similar to stress echocardiography. So, by combining these two tests the investigators want to see if it is possible to see severe as well as small areas of disease in one test, to provide better treatment.\n\nThe study will enrol 2,000 participants, who need investigation for CHD, equally randomised to CTCA or stress echocardiography with carotid ultrasound. We will follow these participants for 5 years and observe for any adverse outcomes and ask them to complete a questionnaire.",[80,81,82],"Chronic Coronary Syndrome","Coronary Disease","Coronary Artery Disease",[84,85,31],"CTCA","Stress Echocardiography","2025-11-20",{"date":88,"type":37},"2025-11-21",{"date":90,"type":37},"2023-09-18",{"date":92,"type":20},"2031-12-31",{"name":43,"class":44},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100608950","texture-and-colour-enhancement-imaging-txi-versus-dye-chromoendoscopy-for-dysplasia-detection-in-ibd-surveillance-100608950","NCT07208214","Texture and Colour Enhancement Imaging (TXI) Versus Dye Chromoendoscopy for Dysplasia Detection in IBD Surveillance.","A Randomised Parallel-group Study of Texture and Colour Enhancement Imaging (TXI) Versus Dye Chromoendoscopy for Dysplasia Detection in IBD Surveillance.","TXIorDyE","Inclusion Criteria:\n\n* Patients \\>16 with inflammatory bowel disease undergoing surveillance colonoscopy.\n\n  * Patients with Crohn's (L2\u002FL3 Montreal classification) with \\>50% colonic involvement\n  * Patients with ulcerative colitis with Extensive or left sided disease (E3 or E2 Montreal classification) for at least 8 years or a diagnosis of Primary sclerosing cholangitis concomitant with IBD.\n\nExclusion Criteria:\n\n* The participant may not enter the study if ANY of the following apply:\n\n  * Disease duration \\\u003C8 years unless a diagnosis of PSC\n  * Incomplete colonoscopy\n  * BBPS \\\u003C6 or \\\u003C2 in any segment\n  * MES ≥2 or any variable of the SES-CD is ≥2 or any stenosis for \\>10cm segment (above the rectum)\n  * Previous colorectal resection\n  * Thrombocytopaenia (platelet count \\\u003C50) or Coagulopathy precluding biopsy\n  * Anticoagulation that has not been held appropriately prior to the procedure (must be held at least the morning of the procedure).\n  * Allergy to Indigo Carmine\n  * Pregnancy\n  * Unable or unwilling to consent to study participation",{"count":103,"type":20},242,[23],"In individuals with inflammatory bowel disease (IBD), bowel cancer can develop from abnormal cell changes (dysplasia). Regular colonoscopies are recommended to identify these early changes, which can be difficult to detect because they are often small and subtle. Dye-based imaging has been used to improve detection, but it requires additional preparation and time. Texture and Colour Enhancement Imaging (TXI) is a newer method available in clinical practice that adjusts brightness, colour, and texture on high-definition cameras. This study will compare TXI with dye-based imaging to assess which approach detects precancerous changes more effectively in patients with IBD.",[59],"NOT_YET_RECRUITING","2025-09-26",{"date":110,"type":37},"2025-10-06",{"date":112,"type":20},"2025-10-01",{"date":114,"type":20},"2027-07-01",{"name":43,"class":44},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":124,"sex":125,"minAge":17,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":45},"100527077","care-for-oasi-study-care-pathways-and-anorectal-evaluation-for-oasi-associated-incontinence-100527077","NCT06143072","CArE for OAsI Study: Care Pathways and Anorectal Evaluation for OASI Associated Incontinence","Referral Pathways and Care Provision for Patients Who Develop OASI Associated Incontinence in the First Five Years Following a Vaginal Delivery","CArE for OAsI","Part 1 of Study\n\nInclusion Criteria:\n\n* • Fertile women ≥ 18 years and ≤50 who have developed OASI related incontinence following a vaginal delivery in the preceding five years (N.B. the average age of menopause in the UK is 51)\n\n  * Tertiary referrals to the specialist perineal clinic as well as patients who have 'slipped' through the existing pathway of referral\n  * Capacity to consent (able to comprehend and retain information, weight out the risks and benefits and communicate a decision back to the researcher)\n  * English-speaking and able to comprehend and read English\n  * Primiparous\u002Fmulti-parous\n\nExclusion Criteria:\n\n* • Women who are unable to consent or who have severe mental illness, as decided by the screening clinician\n\n  * Patients who do not speak, read or understand English\n  * Patients with an alternative documented cause for their FI that is non obstetric trauma related.\n  * Post-menopausal women who may develop late onset symptoms of incontinence relating to a previous OASI (clinically silent injuries that manifest in later life secondary to hormonal influences or advancing age for example).\n  * Women with an OASI who have been referred directly from the maternity unit at the same trust as the specialist perineal clinic, where an existing trust policy exists for direct referral of these patients from the maternity unit to the perineal clinic.\n\nPart 2 of study:\n\nInclusion criteria:\n\n• urogynaecologists\u002Fobstetricians who oversee the care of or look after patients with OASI and who are practising in UK NHS hospitals at the time of completion of the survey. They must be on the GMC specialist register to be eligible to participate\n\nExclusion criteria:\n\n• trainees, obstetricians\u002Fgynaecologists not routinely involved in the care of OASI patients.",true,"FEMALE","50 Years",{"count":128,"type":20},112,"OBSERVATIONAL","The aim of this study is to ascertain which pathways currently exist in relation to the follow up of patients with obstetric anal sphincter injury related incontinence. This is particularly important as afflicted individuals may not readily volunteer information about their symptoms and struggles and need to be safeguarded by the presence of robust care pathways that ensure adequate follow up and care provision.\n\nAs obstetric anal sphincter injuries have been associated with increased litigation rates over the years, positive interventions towards patient care will help ameliorate the financial burden that litigation carries on the National Health Service. It is noteworthy of mention that perineal injury, in itself, may not be suggestive of negligent care and is a recognized complication of vaginal delivery. However, a failure to adequately manage the injury may carry medicolegal implications.",[132,133,134,135,136,137,138,139,140,141,142,143,144,145],"Obstetric Anal Sphincter Injury","Severe Perineal Trauma","Grade 3 Perineal Tear","Grade 4 Perineal Tear","Anal Incontinence","Faecal Incontinence","Urgency","Deferral Time","Pathways","Follow-up","Review","Endo-anal Ultrasound","Urogynaecology","Biofeedback","2025-05-21",{"date":148,"type":37},"2025-05-25",{"date":150,"type":37},"2024-01-01",{"date":152,"type":20},"2025-07-01",{"name":43,"class":44},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":45},"100350992","high-frame-rate-ultrasound-in-heart-disease-assessment-100350992","NCT03850015","High Frame Rate Ultrasound in Heart Disease Assessment","High Frame Rate Contrast Enhanced-ultrasound for the Assessment of Ischaemic Heart Disease","RUFUS-Heart","Inclusion criteria Either\n\n* Ability to give informed consent\n* age ≥18years and\n* confirmed inducible wall motion \u002F perfusion abnormality on previous stress echocardiogram\n* known coronary artery disease - defined by presence of flow-limiting coronary stenosis(\\>70% diameter stenosis) on coronary angiography.\n\nOR\n\n• patient who has been assessed as at low risk of having coronary heart disease\n\nExclusion Criteria:\n\n* Inability to undertake pharmacological stress, ie previously known intolerance to dipyridamole;\n* Moderate or Severe aortic or mitral regurgitation or severe mitral stenosis;\n* Significant pulmonary disease like severe COPD or pulmonary fibrosis;\n* Atrial fibrillation;\n* Inability to provide informed consent;\n* Pregnancy and lactation;\n* Known allergy to Sonovue\n* Patients with second and third degree heart block, unless they have a pacemaker fitted\n* Systolic BP \\\u003C 90\n* Known Myasthenia Gravis\n* Bronchial asthma",{"count":163,"type":20},25,"The study will compare standard ultrasound images to high frame rate ultrasound images in patients with heart disease or with a low risk of heart disease to see if a higher frame rate of ultrasound adds to the information obtained from standard ultrasound.",[82],[167],"echocardiography",{"date":169,"type":37},"2025-05-23",{"date":171,"type":37},"2022-02-01",{"date":173,"type":20},"2025-09-30",{"name":43,"class":44},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":124,"sex":16,"minAge":17,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":195,"leadSponsor":197,"locationsCount":45},"100550506","psylived-the-psychological-impacts-of-living-with-an-inherited-colorectal-cancer-predisposition-syndrome-100550506","NCT06447961","PSYLIVED: the Psychological Impacts of Living With an Inherited Colorectal Cancer Predisposition Syndrome","The Psychological Impacts of Living With an Inherited Colorectal Cancer Predisposition Syndrome","PSYLIVED","Inclusion Criteria:\n\n* Adults aged 18 years or older, residing in the UK.\n* Diagnosed with inherited colorectal cancer or likely to have inherited colorectal cancer and have been offered genetic testing for this reason.\n* Possess the capacity to provide informed consent.\n* Able to communicate in English.\n\nExclusion Criteria:\n\n* Under 18 years old.\n* Unable to communicate in English.\n* Experience significant learning or communication difficulties.\n* Reside outside of the UK.","99 Years",{"count":185,"type":20},66,"Why? PSYLIVED is a qualitative study that aims to understand the psychological experience of individuals living with inherited colorectal cancer. It addresses the question of how individuals cope emotionally and adapt to the unique challenges they face. This research sheds light on the emotional journey of those with inherited colorectal cancer, potentially leading to improved support services, interventions, and care practices tailored to their needs. The study seeks to enhance the well-being of patients undergoing genetic testing and contribute to better services and support practices.\n\nWhat? PSYLIVED is a qualitative study that will employ reflexive Thematic Analysis methodology to explore the emotional responses and experiences of participants over time.\n\nWho? The investigators are interested in interviewing between 30 to 66 individuals who have first-hand experience of being at risk or having an inherited colorectal cancer syndrome.\n\nWhere? While the study is conducted by the St Mark's Centre for Familial Intestinal Cancer, this study is open to individuals in the UK. Interviews will primarily be conducted via telephone or Microsoft Teams to facilitate accessibility. However, participants residing near London who prefer face-to-face interviews will be offered this option.\n\nHow? Each participant will take part in a one-hour audio-recorded interview where they will be asked to talk about their experiences. The interview will be recorded, so it can be transcribed word by word. During the transcription, the interview will be anonymised to ensure confidentiality. The responses will then be compared and analysed to create a result summary, along with interviews from other individuals with similar experiences. The study is set to commence in June 2024, with recruitment open for approximately two years.",[188,189,190],"Lynch Syndrome","Polyposis Syndrome, Hereditary Mixed, 1","Polyposis Syndrome, Hereditary Mixed, 2","2024-06-18",{"date":193,"type":37},"2024-06-21",{"date":191,"type":37},{"date":196,"type":20},"2026-08-01",{"name":43,"class":44},""]